MOVE

MOVE is not the company its financials describe. Every figure here reflects the pre-merger Healthcare Business (the former Movano 'Evie' wellness ring), which management explicitly states 'are not inclusive of the financial position, results of operations and cash flows of Corvex OpCo' — the AI Cloud Computing (GPU infrastructure) business that closed via the March 19, 2026 merger and is now the actual go-forward entity. You are therefore valuing a stub. The legacy numbers are grim on their own terms: FY2025 revenue of just $433K fell 57.3% YoY, operating margin is -3,580%, stockholders' equity is negative (-$3.47M), liabilities/equity is -2.61x, and the accumulated deficit is -$166M. Cash of $2.83M against -$11.3M operating cash burn implies the old business was months from insolvency — which is precisely why it was reverse-merged into.

The capital structure is the disqualifying problem. Reported shares outstanding are only 1.21M (after an 82.8% reduction — a reverse split), producing a superficially small $21M market cap and a nonsensical 48.5x P/S on stale revenue. But the MD&A discloses that merger consideration includes 240.562 Series B (→ ~240K common), 23,551.5195 Series C (→ ~23.6M common) and 30,227.0524 Series D (→ ~30.2M common) preferred shares that convert at 1,000-to-1. That is roughly 54M new common shares — more than 40x the current count — plus a $1.0 billion equity facility with Chardan and a $3.0M Series A raise. The dilution overhang is enormous and essentially none of it is reflected in the price or share count you see.